Clinical activity and tolerability of the RET inhibitor BLUE-667 in patients with advanced RET fusion and NSCLC

Understanding eligibility criteria for clinical trials to increase study size

Expanded clinical trial inclusion criteria would double the percentage of patients eligible to enrol in clinical trials

Clinical and translational results from the NEOSTAR study: Treating early-stage lung cancer with nivolumab plus ipilimumab

KEYNOTE-001: Five year data from the phase Ib trial studying pembrolizumab as treatment for aNSCLC

Pembrolizumab is safe and effective and substantially increases overall survival in aNSCLC patients

Comment: The success of immunotherapy means we have to change our mindset as we treat patients

Cardiac events following radical radiotherapy for lung cancer

ALK-positive NSCLC: Treatments and latest developments

ALK-positive NSCLC: Current landscape

Latest data from KEYNOTE 42: Pembrolizumab vs chemotherapy in treatment-naive patients (pts) with PD-L1 advanced NSCLC

Entrectinib in NTRK fusion-positive non-small cell lung cancer